All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-03-26T09:01:54.000Z

EBMT 2018 | Comparison of safety outcomes between PTCy-based haploidentical and HLA-matched related or unrelated donor transplantation for patients with R/R aggressive NHL

Mar 26, 2018
Share:

Bookmark this article

An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-2 was presented by Sarah Haebe, from the Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, Ludwig-Maximilians University, Munich, Germany which compared the safety and efficacy of post-transplantation cyclophosphamide (PTCy)-based haploidentical donor (haplo-D) transplantation versus HLA-matched related donor (MRD) or unrelated donor (URD) transplantation in refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (aNHL).

In this study, patients treated with T-cell replete (TCR) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were matched-paired with patients receiving HLA-matched transplantation (MRD and URD). The age (± 5 years) and the stage at HSCT (defined as complete response [CR] or non-CR) varied between pair-matched patients in this analysis. The primary endpoints of this study were overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM) and graft-versus-host disease (GvHD) incidence.

Demographics

  • N = 21 patients in each group (TCR/PTCy haplo-HSCT, MRD and URD)
  • Successful match-pair single center analysis of 21 haplo-HSCT with 21 MRD and 21 URD patients
  • Median age of all patients (range): 48 (20–65)
  • Histology (all patients):
    • Aggressive NHL: 62%
    • Indolent NHL: 22%
    • T-cell NHL (T-NHL): 16%
  • Median number of prior therapies (range): 4 (2–6)
  • Conditioning regimen (all patients):
    • Reduced intensity conditioning (RIC): 58%
    • Non-myeloablative conditioning(NMA): 21%
    • Myeloablative conditioning (MAC): 21%

Key Findings

  • Median follow-up: 39 months
  • CR at Day +30 (all patients) = 84%;
  • Median time to engraftment (days; P = 0.2):
    • MRD = 16
    • URD = 18
    • Haplo = 20
  • PFS and OS at 2-years (%):
    • MRD = 33 and 43
    • URD = 19 and 38
    • Haplo = 43 and 52
  • PFS and OS at 3-years (%):
    • MRD = 29 and 33
    • URD = 19 and 38
    • Haplo = 38 and 52
  • Occurrence of acute GvHD II–IV at 100-days follow-up (%; P = 0.03):
    • MRD = 30
    • URD = 55
    • Haplo = 21
  • Occurrence of chronic GvHD (moderate and severe) at one year follow-up (%; P = 0.4):
    • MRD = 39
    • URD = 35
    • Haplo = 20
  • Non-relapse mortality (NRM) within one year after transplantation (%):
    • MRD = 2
    • URD = 33
    • Haplo = 24
  • Relapse rate within the first year after transplantation (%):
    • MRD = 29
    • URD = 38
    • Haplo = 24
  • Death from aplasia = 6 patients

The results from this study demonstrated similar outcomes between patients treated with haplo-HSCT using PTCy and patients who received HLA-matched transplantation. With a higher incidence of acute GvHD and NRM rates after URD transplantation, the authors suggested that haplo-HSCT might be used as an efficient safer alternative regimen for patients with aNHL.

  1. Sarah Haebe et al. T-cell replete HLA-haploidentical transplantation using PTCy versus HLA-matched related/unrelated donor transplantation in refractory or relapsed aggressive NHL- Results of a single center matched-pair analysis. Oral abstract OS1-2. EBMT 44th Annual Meeting, Lisbon, Portugal.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox